Keywords
Abstract
We studied 83 patients with pulmonary tuberculosis, combined with diabetes mellitus, who were divided into 2 groups. The first group included 46 patients who received pentoxifylline for the correction of metabolic status of the vascular endothelium and the plasma sys- tem of hemostasis. The comparison group consisted of37 patients, in the treatment of which pentoxifylline was not used. It was found that under the influence of pen- toxifylline, the level of the potent vasodilator of nitric ox- ide increases with the simultaneous decrease in the level of the vasoconstrictor - endothelin 1, the level of the marker of damage to the vascular endothelium - von Willebrand factor is reduced and the hypercoagulable changes is normalized. Inclusion in the complex therapy of patients with pulmonary tuberculosis, combined with diabetes mellitus as a pathogenetic agent of pentoxifyl- line, increases the efficacy of treatment of this category of patients. After 6 months of treatment, sputum smear negative in patients who received pentoxifylline as a pathogenetic agent was observed in 76%, and in the comparison group in 51.3% of cases (p<0.01).This effectof the drug is due to its distinct positive influence on the metabolic status of the vascular endothelium on the one hand, and on the hemostatic system on the other, which greatly improves the access of medications to the lesion focus.